ClinicalTrials.gg
Not yet recruitingNCT07946315TREAT-IIHUpdated Nov 18, 2026

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension

A Phase 2 interventional study of Tirzepatide and Placebo in Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri and Papilledema, sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Pseudotumor Cerebri with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Pseudotumor Cerebri · United States.

Planned enrollment
5th of 12
75 · median 50
Started
2027
the only one that year
Phase 2
Only one
of the 17
Registered
17th of 17
by date
Lead sponsor
1 of 17
Brigham and Women's Hospital

Among the 17 studies in Pseudotumor Cerebri with a site in United States, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 2, and was the 17th registered.

Pseudotumor Cerebri

54 studies on the registry are indexed under Pseudotumor Cerebri; 23 are open to participants now.

Browse Pseudotumor Cerebri studies →

Open to participants now

3 of the 17 studies in Pseudotumor Cerebri with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Pseudotumor Cerebri studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pseudotumor Cerebri with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are:

  • Does tirzepatide lower the mean daily acetazolamide dose at 12 months?
  • Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension?

Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache.

In addition to receiving treatment with acetazolamide, participants will:

  • Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation.
  • Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing.
  • During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment.
  • Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.
Read the detailed description

Background. Acetazolamide is the current standard medical therapy for IIH and acts through inhibiting CSF production by the choroid plexus epithelium. The IIH Treatment Trial showed that acetazolamide improves visual field mean deviation, papilledema, and weight loss versus placebo, but the absolute effects were modest, headache was not significantly improved, and tolerability of acetazolamide remains a limitation. Tirzepatide and other GLP-1 agonists have potential benefit in IIH since they are effective for weight loss, and IIH can be put into remission with roughly 25% weight loss. Direct lowering of ICP by a mechanism similar to acetazolamide was also demonstrated for exenatide, another GLP-1 agonist. It is unclear if this ability extends to other members of the GLP-1 agonist class, but it is an appealing possibility.

Design. This is a single-center, randomized, double-masked, placebo-controlled, parallel-group phase 2 trial, reported per CONSORT 2025. Randomization is 1:1, administered by the BWH Research Pharmacy, stratified by (a) papilledema grade/visual loss severity and (b) BMI category, using permuted blocks of varying size. Participants, treating clinicians, outcome assessors, and analysts are masked; only unblinded pharmacy staff know allocation.

Intervention. All participants receive extended-release acetazolamide starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), and up-titrated to a maximum of 4 g/day. Acetazolamide dose is titrated at study visits by predefined rules based on perimetric mean deviation, papilledema (Frisén grade, OCT pRNFL), and a 14-day headache score. Participants also self-inject weekly tirzepatide or matching placebo starting at 2.5 mg one week after acetazolamide initiation, increasing monthly (5, 7.5, 10, 12.5 mg) to a maximum of 15 mg weekly as tolerated. All participants receive standardized nutrition and exercise guidance.

Visits. Screening/baseline, then visits at months 1, 2, 3, 5, 7, 10, and 12, with telephone or video contacts at months 4, 6, 8, 9, and 11. Assessments include visual acuity, automated perimetry (HVF 24-2 SITA Standard), OCT (Cirrus; Spectralis at baseline and 12 months), OCT angiography, fundus photography, weight and abdominal circumference, headache/quality-of-life/sleep questionnaires, lumbar puncture at month 12, and DXA and MRI at baseline and 12 months. After month 12, participants are followed open-label through month 24.

Primary endpoint is mean daily acetazolamide dose at the 12-month visit in participants with baseline BMI ≥27.0.

Statistics. Sample size is based on detecting a 375 mg/day difference (SD 450 mg, two-sided alpha 0.05, 80% power), requiring about 47 completers, inflated for 30% loss to follow-up. The primary analysis is a mixed linear model adjusted for stratification factors with a random site intercept. One interim analysis is planned using a group-sequential design (Lan-DeMets O'Brien-Fleming alpha spending) with a one-time promising-zone sample size adaptation.

Safety. Adverse events are graded with CTCAE v6.0. Medical and statistical monitors review safety data. Predefined criteria govern withdrawal and treatment failure.

03

Conditions studied

  • Idiopathic Intracranial Hypertension (IIH)
  • Pseudotumor Cerebri
  • Papilledema

Keywords

  • Idiopathic Intracranial Hypertension
  • Tirzepatide
  • Acetazolamide
  • GLP-1 receptor agonist
  • GIP receptor agonist
  • papilledema
  • headache
  • weight loss
  • obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial:

    (i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure >25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause of secondary intracranial hypertension (e.g., tumor, hydrocephalus, venous sinus thrombosis)

  • ≥25
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Treatment for IIH for more than 30 days in the prior year with any agent (acetazolamide, topiramate, furosemide, zonisamide, GLP-1 or dual GLP-1/GIP agonist); if on acetazolamide in the prior month, dose must not have exceeded 1 g/day
  • IIH relapse at prescreen/screen
  • Prior intracranial shunting, venous sinus stenting, or optic nerve sheath fenestration
  • Bariatric surgery within the past year
  • New cranial nerve dysfunction other than papilledema and sixth nerve palsy
  • Major CT/MRI abnormalities suggesting secondary intracranial hypertension or alternate diagnosis (e.g., hydrocephalus, Chiari malformation, dural AV fistula, venous sinus thrombus, retrobulbar optic nerve enhancement suggesting optic neuritis)
  • History of optic neuritis, multiple sclerosis, MOG antibody disease, neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, or seropositivity for MOG or aquaporin-4 antibodies
  • Exposure for >7 days within 2 months of symptom onset to an oral drug, substance, or disorder potentially affecting ICP (e.g., vitamin A derivatives, tetracyclines, growth hormone, lithium, )
  • CSF leak confirmed by beta-2 transferrin within 1 month of enrollment
  • Media opacity precluding adequate OCT signal strength and Frisén grading
  • Unreliable automated perimetry (≥30% fixation losses, ≥20% false positives or negatives) at screening
  • PMD of -15 dB or worse on reliable perimetry
  • Comorbid condition requiring diuretics, systemic steroids, or other ICP-lowering agents including topiramate or zonisamide (nasal, inhaled, or topical steroids permitted)
  • Intraocular pressure currently >28 mmHg or >30 mmHg at any time in the past
  • Refractive error greater than ±8.00 sphere or ±3.00 cylinder in either eye if associated with anatomic abnormalities that could cause visual loss
  • Optic disc drusen on fundus examination or OCT
  • Other disorders causing visual loss except refractive error and amblyopia
  • Lab abnormalities or conditions contraindicating acetazolamide (severe anemia, leukopenia, thrombocytopenia, renal failure, hepatic disease, calcium phosphate or calcium oxalate nephrolithiasis)
  • Lab abnormalities or conditions contraindicating GLP-1/GIP agonist use, including type 1 diabetes, diabetic retinopathy, diabetes managed with insulin or a secretagogue, current hypoglycemia, gallbladder disease, pancreatitis, or personal or family history of medullary thyroid cancer
  • Pregnancy, or unwillingness of participants of to use two methods of , including a non-pharmacologic barrier method, during the study and for 1 month after
  • Breastfeeding, unless willing to stop by the baseline visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Acetazolamide + Tirzepatide

    Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling.

    Drug: Tirzepatide · Drug: Acetazolamide

  • Placebo comparator
    Acetazolamide + Placebo

    Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling.

    Drug: Placebo · Drug: Acetazolamide

Interventions

  • Weekly subcutaneous self-injection via autoinjector, starting 1 week after acetazolamide initiation at 2.5 mg and increasing every month to 5, 7.5, 10, 12.5, and 15 mg weekly as tolerated. Down-titration by one step and discontinuation at 2.5 mg are allowed for intolerance. Other names: Mounjaro; Zepbound.

  • DrugPlacebo

    Weekly subcutaneous placebo injection matched to tirzepatide in appearance and delivery device, with the same dose-escalation schedule.

  • Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day.

06

What researchers measure

Primary outcomes

  1. Mean daily acetazolamide dose at 12 months

    Mean daily acetazolamide dose (mg/day) at 12 months in participants with baseline BMI ≥27.0

    Time frame: 12 months

Secondary outcomes

  1. Cumulative acetazolamide dose

    Area under the curve (cumulative dose) of acetazolamide over the study

    Time frame: Baseline to 12 months

  2. Between-group comparison of acetazolamide dose at each study visit

    Time frame: Months 1, 2, 3, 5, 7, 10, 12

  3. Time to initiation of acetazolamide down-titration (days)

    Time frame: Baseline to 12 months

  4. Remission rate (off acetazolamide)

    Proportion of participants off acetazolamide (remission) at 12 months and sustained through the subsequent visit.

    Time frame: Baseline to 15 months

  5. Best-corrected visual acuity

    Change in best-corrected visual acuity (ETDRS, logMAR) in each eye. ≥0.3 logMAR (15-letter) change considered significant difference.

    Time frame: Baseline to 12 months

  6. Visual field perimetric mean deviation

    Change in perimetric mean deviation (HVF 24-2 SITA Standard)

    Time frame: Baseline to 12 months

  7. Papilledema Frisén grade

    Change in Frisén papilledema grade from fundus photographs (masked grader), and mean grade at each visit.

    Time frame: Baseline to 12 months

  8. Peripapillary retinal nerve fiber layer (pRNFL) thickness

    Change in mean pRNFL thickness (microns) measured using optical coherence tomography (Cirrus device)

    Time frame: Baseline to 12 months

  9. Combined ganglion cell-inner plexiform layer (GCIPL) thickness

    Change in macular ganglion cell-inner plexiform layer (GCIPL) thickness (Cirrus, microns) measured using optical coherence tomography.

    Time frame: Baseline to 12 months

  10. Peripapillary capillary density on optical coherence tomography angiography (OCT-A)

    Change in peripapillary capillary density on OCT-A (Cirrus)

    Time frame: Baseline to 12 months

  11. Change in lumbar puncture opening pressure

    LP opening pressure measured in cm cerebrospinal fluid (CSF)

    Time frame: Baseline to 12 months

  12. Proportion of patients with new spontaneous cerebrospinal fluid leak

    Time frame: Baseline to 12 months

  13. Composite National Eye Institute Visual Function Questionnaire 25 (VFQ-25) plus 10-item neuro-ophthalmology supplement score

    Measure of vision-related quality of life and self-reported health status on a scale of 0-100. A higher score indicates better quality of life.

    Time frame: Baseline to 12 months

  14. Migraine disability assessment test (MIDAS)

    5-item questionnaire measuring headache-related disability over a 3 month period. Score is the sum of days from individual questions. Higher scores signify greater headache disability. Score ranges from 0-270.

    Time frame: Baseline, months 3, 7, 12

  15. Headache impact test (HIT-6)

    6 item questionnaire measuring how headaches affect daily life, work and social activities. Score ranges from 36 (no impact) to 78 (severe impact).

    Time frame: Baseline, months 3, 7, 12

  16. 14-day headache score

    Count of days with headache lasting more than 4 hours or requiring acute medical treatment within the prior 14 days.

    Time frame: Baseline, months 1-12

  17. Time to symptom control

    Time (days) to symptom control (\<4 symptom days/month of headache, pulsatile tinnitus, or transient visual obscuration).

    Time frame: Baseline to 12 months

  18. Proportion with symptom control

    Proportion of patients with symptom control (\<4 days/month of headache, pulsatile tinnitus, or transient visual obscuration)

    Time frame: Baseline to 12 months

  19. Brain fog scale score

    23 item questionnaire with total score ranging from 0 to 92. Higher scores indicate increased levels of brain fog.

    Time frame: Baseline to months 3, 7, 12

  20. Percent reduction in body weight

    Percent reduction in body weight. Positive value represents weight loss and negative value represents weight gain.

    Time frame: Baseline to 12 months

  21. Body Mass Index (BMI)

    Change in BMI measured in kg/m2. Positive value represents an increase in BMI and a negative value represents a decrease in BMI.

    Time frame: Baseline to 12 months

  22. Abdominal circumference

    Change in abdominal circumference (cm). Positive value represents increase in circumference, and negative value represents a decrease in circumference.

    Time frame: Baseline to 12 months

  23. Body fat mass

    Change in dual-energy x-ray absorptiometry (DXA) measure of body fat mass (kg). Positive value represents an increase in body fat mass, and negative value represents a reduction in body fat mass.

    Time frame: Baseline to 12 months

  24. Percent body fat

    Change in dual-energy x-ray absorptiometry (DXA) measures of percent body fat. Positive value represents an increase in percent body fat, and negative value represents a reduction in percent body fat.

    Time frame: Baseline to 12 months.

  25. Android/gynoid ratio

    Dual-energy x-ray absorptiometry (DXA) measure of android/gynoid ratio change. A/G ratio is the percentage or mass of android (abdominal) fat divided by the gynoid (hip/thigh) fat. A higher ratio (\>1.0) indicates more weight is carried in the midsection. A lower ratio (\<1.0) indicates more weight is carried in the hips and thighs. Increase in A/G ratio indicates an increase in abdominal/visceral fat relative to hip/thigh fat, while a decrease in A/G ratio indicates a reduction in abdominal/visceral fat relative to hip/thigh fat.

    Time frame: Baseline to 12 months

  26. Bone mineral density

    Change in dual-energy x-ray absorptiometry (DXA) measure of bone mineral density (g/cm2). Positive value represents an increase in bone mineral density, and negative value represents reduction in bone mineral density.

    Time frame: Baseline and 12 months.

  27. Structural magnetic resonance imaging (MRI) features of intracranial hypertension

    Change in the number of structural MRI features of intracranial hypertension (partially empty sella, optic nerve sheath distention, posterior globe flattening, and presence of transverse venous sinus stenosis). Score ranges from -4 to 4. Negative score indicates resolution of findings, and a positive score indicates development of additional findings.

    Time frame: Baseline to 12 months

  28. Pituitary gland height

    Maximum pituitary gland height (mm) measured orthogonal to the sellar floor on mid-sagittal T1 weighted MRI sequence.

    Time frame: Baseline to 12 months

  29. Optic nerve sheath diameter (mean)

    Maximum diameter of the optic nerve sheath as measured on axial T2 weighted MRI within the orbit, averaged between right and left

    Time frame: Baseline and 12 months

  30. Combined conduit score (CCS)

    Using 3D T1-weighted MRI and MR venogram time-of-flight sequences, each transverse-sigmoid sinus conduit (right and left) is evaluated between the torcula and distal sigmoid sinus. The degree of narrowing on each side is assigned a value: 0 - aplastic or flow gap; 1 - hypoplastic or narrowed to \<25% expected diameter; 2 - narrowed to 25-50% expected diameter; 3 - narrowed to 50-75% expected diameter; 4 - narrowed to 75-100% expected diameter). The CCS is the sum of the scores of the right and left side and ranges from 0 to 8. From Farb et al. 2003.

    Time frame: Baseline to 12 months

  31. Diffusion tensor imaging along the perivascular space (DTI-ALPS) index

    Change in ALPS index. It is calculated as a ratio of water diffusivity values measured along different axes in specific white matter regions near the lateral ventricles to isolate perivascular diffusivity. ALPS indices are unitless. An increase in ALPS index represents an increase in extracellular/glymphatic fluid transit.

    Time frame: Baseline to 12 months.

  32. Epworth Sleepiness Scale (ESS)

    Change in ESS. Score ranges from 0 to 24. Increase in ESS indicates worsened symptoms related to obstructive sleep apnea.

    Time frame: Baseline to 12 months

  33. STOP-Bang score (S-Snoring; T-Tired; O-Observed; P-Pressure; B-BMI; A-Age; N-Neck; G-Gender)

    Change in STOP-Bang score. Score ranges from 0 to 8. Increase in STOP-Bang indicates worsened symptoms related to obstructive sleep apnea (OSA).

    Time frame: Baseline to 12 months

  34. Apnea-hypopnea index (AHI)

    Change in apnea-hypopnea index (AHI) in patients with obstructive sleep apnea (OSA) who also complete a follow up sleep study at 12 months. AHI are the number of breathing disturbances/hour during sleep. An increase in AHI indicates worsening of sleep disorder breathing/OSA, while a decrease in AHI indicates improvement.

    Time frame: Baseline to 12 months.

  35. Adverse Events

    Number of participants with adverse events (AE) (CTCAE v6.0)

    Time frame: Baseline to 24 months

  36. Serious Adverse Events

    Number of participants with severe adverse events

    Time frame: Baseline to 24 months

  37. Treatment-related withdrawals

    Number of participants with treatment-related withdrawals

    Time frame: Baseline to 12 months

  38. Treatment failures

    Number of patients with treatment failures

    Time frame: Baseline to 12 months

07

Study locations

1 site
  • Brigham and Women's Hospital
    Boston, Massachusetts 02446, United States
    • Eleonore Kugener · ContactIIH-TRI@mgb.org · 617-525-3610
    • Robert Mallery, MD · ContactIIH_TRI@mgb.org · 617-525-3610
    • Robert Mallery, MD · Principal investigator
    • Marc Bouffard, MD · Sub investigator
    • Bart Chwalisz, MD · Sub investigator
08

References and documents

Publications

  • Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, terBrugge KG. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003 May 13;60(9):1418-24. doi: 10.1212/01.wnl.0000066683.34093.e2. PubMed 12743224 ↗
  • Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomized trials. Nat Med. 2025 Jun;31(6):1776-1783. doi: 10.1038/s41591-025-03635-5. Epub 2025 Apr 15. PubMed 40229553 ↗
  • Sioutas GS, Mualem W, Reavey-Cantwell J, Rivet DJ 2nd. GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. JAMA Neurol. 2025 Sep 1;82(9):887-894. doi: 10.1001/jamaneurol.2025.2020. PubMed 40658395 ↗
  • Kravetz L, Leeman S, Regev T, Walter E, Horev A, Ofri M, Kerman T, Watted M, Buklan K, Hin W, Elobra Y, Tsumi E. The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study. Eye (Lond). 2025 Jul;39(10):2090-2095. doi: 10.1038/s41433-025-03807-0. Epub 2025 Apr 29. PubMed 40301667 ↗
  • Friedman DI, Quiros PA, Subramanian PS, Mejico LJ, Gao S, McDermott M, Wall M; and the NORDIC IIHTT Study Group. Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial. Headache. 2017 Sep;57(8):1195-1205. doi: 10.1111/head.13153. Epub 2017 Jul 28. PubMed 28752894 ↗
  • Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013 Sep 24;81(13):1159-65. doi: 10.1212/WNL.0b013e3182a55f17. Epub 2013 Aug 21. PubMed 23966248 ↗
  • Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, Novak K, Wober C, Pemp B, Bsteh G. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023 Jul 18;24(1):89. doi: 10.1186/s10194-023-01631-z. PubMed 37460968 ↗
  • Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023 May 2;146(5):1821-1830. doi: 10.1093/brain/awad003. PubMed 36907221 ↗
  • NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312. PubMed 24756514 ↗
  • Mollan SP, Mitchell JL, Ottridge RS, Aguiar M, Yiangou A, Alimajstorovic Z, Cartwright DM, Grech O, Lavery GG, Westgate CSJ, Vijay V, Scotton W, Wakerley BR, Matthews TD, Ansons A, Hickman SJ, Benzimra J, Rick C, Singhal R, Tahrani AA, Brock K, Frew E, Sinclair AJ. Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial. JAMA Neurol. 2021 Jun 1;78(6):678-686. doi: 10.1001/jamaneurol.2021.0659. PubMed 33900360 ↗

Individual participant data

Plan to share: No — We did not seek MGB IRB approval for data sharing outside of Mass General Brigham.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for May 2030, 40 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
May 1, 2030
CompletionEst.
May 1, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946315
Responsible party
Robert Mallery (Assistant Professor of Neurology, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
May 1, 2030 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Eleonore Kugener, MS
Contact
IIH-TRI@mgb.org
617-525-3610
Robert Mallery, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion